Vaccine compositions and methods for restoring NKG2D pathway function against cancers
First Claim
Patent Images
1. A vaccine composition for treating cancer, the composition comprising(i) as an immunogenic component, an effective amount of a peptide consisting of:
- (a) amino acids 181 to 274 of SEQ ID NO;
1;
(b) SEQ ID NO;
2, 11, 12, 13, 21 or 23;
(c) SEQ ID NO;
11, 12, 13, 21 or 23, further comprising 2, 4, 5, 6, 8, or 10 flanking amino acids on either the N-terminal end of the peptide, the C-terminal end of the peptide, or both the N-terminal end and the C-terminal end of the peptide;
or(d) SEQ ID NO;
11, 12, 13, 21 or 23, further comprising one or more flanking amino acids such that the entire peptide consists of about 25 to 30 amino acids;
the effective amount being an amount effective to elicit an immune response against the cancer;
wherein flanking amino acids are amino acids adjacent to SEQ ID NO;
11, 12, 13, 21 or 23 in SEQ ID NO;
1 or in SEQ ID NO;
14; and
(ii) an adjuvant selected from an oil-based adjuvant, a CpG DNA adjuvant, a mineral salt adjuvant, a particulate adjuvant, a mucosal adjuvant, a cytokine, a microbial derivative, an emulsion and a Toll-Like Receptor agonist.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC polypeptide.
79 Citations
25 Claims
-
1. A vaccine composition for treating cancer, the composition comprising
(i) as an immunogenic component, an effective amount of a peptide consisting of: -
(a) amino acids 181 to 274 of SEQ ID NO;
1;(b) SEQ ID NO;
2, 11, 12, 13, 21 or 23;(c) SEQ ID NO;
11, 12, 13, 21 or 23, further comprising 2, 4, 5, 6, 8, or 10 flanking amino acids on either the N-terminal end of the peptide, the C-terminal end of the peptide, or both the N-terminal end and the C-terminal end of the peptide;
or(d) SEQ ID NO;
11, 12, 13, 21 or 23, further comprising one or more flanking amino acids such that the entire peptide consists of about 25 to 30 amino acids;the effective amount being an amount effective to elicit an immune response against the cancer; wherein flanking amino acids are amino acids adjacent to SEQ ID NO;
11, 12, 13, 21 or 23 in SEQ ID NO;
1 or in SEQ ID NO;
14; and(ii) an adjuvant selected from an oil-based adjuvant, a CpG DNA adjuvant, a mineral salt adjuvant, a particulate adjuvant, a mucosal adjuvant, a cytokine, a microbial derivative, an emulsion and a Toll-Like Receptor agonist. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeDana-Farber Cancer Institute
-
Original AssigneeDana-Farber Cancer Institute
-
InventorsDranoff, Glenn, Wucherpfennig, Kai W, Harvey, Christopher, Hodi, F. Stephen
-
Primary Examiner(s)Canella, Karen A.
-
Application NumberUS15/125,882Publication NumberTime in Patent Office1,513 DaysField of SearchNoneUS Class CurrentCPC Class CodesA61K 2039/5152 Tumor cellsA61K 2039/6037 Bacterial toxins, e.g. diph...A61K 39/0011 Cancer antigensA61K 45/06 Mixtures of active ingredie...A61P 35/00 Antineoplastic agentsA61P 43/00 Drugs for specific purposes...C07K 14/70539 MHC-molecules, e.g. HLA-mol...
